Vaginal Diazepam for the Treatment of Female Pelvic Pain

Pelvic Pain Clinical Trial

Official title:

Intravaginal Diazepam for the Treatment of Pelvic Pain Among Women With Pelvic Floor Hypertonic Disorder: a Double Blind, Randomized, Placebo Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01938092
• Other study ID #: 1208827
• Status: Completed
• Phase: Phase 2
• First received: August 30, 2013
• Last updated: July 25, 2017
• Start date: September 2013
• Est. completion date: July 2017

Study information

• Verified date: July 2017
• Source: University of Missouri-Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the efficacy of intravaginal diazepam for the treatment of pelvic pain associated with pelvic floor hypertonic disorder.

Description:

Women who are asked to participate will already be receiving a standard conservative therapy consisting of a psyllium-based bowel regimen, heat therapy, pelvic stretching exercises, and Kegel exercises. Participants will randomly be assigned by a computer-derived random number sequence (after pregnancy is ruled out) to either the treatment group (intravaginal diazepam) or the placebo group Investigators and patients will be blinded to group assignment. The placebo or diazepam tablet will be distributed to the participant in the examining room on the day of allocation. The participant will be instructed to insert the diazepam or placebo tablet into her vagina at home. The treatment group will insert the diazepam 10 mg vaginal tablet 1-2 times daily as needed in addition to the standard conservative therapy. The placebo group will receive the standard conservative therapy, and an intravaginal tablet (visually indistinguishable from diazepam) commercially produced by the university pharmacy. After 4 weeks, patients from either group will have the option of enrolling into a standard routine program (not research) of comprehensive pelvic floor rehabilitation therapy. The Visual Analog Pain Scale, Pelvic Floor Distress Inventory-20 Questionnaire, McGill Pain Questionnaire and Global Response Assessment will be completed by the participant at the initial visit, 4 weeks, 8 weeks and 12 weeks. Participants will be given the option of choosing one or more methods for returning questionnaires: electronic mail, self-addressed home envelope, or telephone call.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years old

• Primary complaint of acute or chronic pelvic pain with or without dyspareunia

• Physical exam findings consistent with levator muscle spasm

• Capable of inserting tablet in vagina without use of applicator.

Exclusion Criteria:

• Chronic narcotic use

• Non-English speaking

• Currently serving a prison sentence

• Stage III or greater vaginal prolapse

• Allergies or contraindications to benzodiazepines

• Pregnant or breastfeeding

• Currently receiving comprehensive pelvic floor rehabilitation therapy and/or vaginal valium therapy

• Unwilling or incapable of inserting tablet in vagina without applicator.

Related Conditions & MeSH terms

• Pelvic Floor Disorders
• Pelvic Pain

Intervention

Drug:
• Diazepam

• Placebo

Locations

Country	Name	City	State
United States	Missouri Center for Female Continence and Advanced Pelvic Surgery, University of Missouri Health System	Columbia	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
University of Missouri-Columbia

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in Visual Analog Pain Scale score at 4 weeks, 12 weeks, and 24 weeks.	Ten centimeter linear scale where patients mark their self-perceived level of pain. The change in pain from the initial visit will be measured at 4 weeks, 12 weeks, and 24 weeks.	Initial visit, 4 weeks, 12 weeks, 24 weeks
Secondary	Change from baseline in Pelvic Floor Distress Inventory-20 Questionnaire score at 4 weeks, 12 weeks, and 24 weeks.	The PFDI-20 is both a symptom inventory and a measure of the degree of bother and distress (quality-of-life) caused by pelvic floor symptoms. Includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The change in PFDI-20 score from the initial visit will be measured at 4 weeks, 12 weeks, and 24 weeks.	Initial visit, 4 weeks, 12 weeks, 24 weeks
Secondary	Change from baseline in McGill Pain Questionnaire score at 4 weeks, 12 weeks, and 24 weeks.	Used to evaluate a person experiencing significant pain. It can be used to monitor the pain over time and to determine the effectiveness of any intervention. It asks the participant what the pain feels like, how it changes with time, and how strong it is. The change in symptoms from baseline measured by this questionnaire will be measured at 4 weeks, 12 weeks ,and 24 weeks.	Initial visit, 4 weeks, 12 weeks, 24 weeks.
Secondary	Change from baseline in Global Response Assessment score at 4 weeks, 12 weeks, and 24 weeks.	Used to evaluate patients' perceptions of treatment effectiveness. The change in the GRA from from the initial visit will be measured at 4 weeks, 12 weeks, and 24 weeks.	Initial visit, 4 weeks, 12 weeks, 24 weeks